← Back to Screener
Senti Biosciences, Inc. Common Stock (SNTI)
Price$1.14
Favorite Metrics
Price vs S&P 500 (26W)-43.66%
Price vs S&P 500 (4W)10.07%
Market Capitalization$34.26M
All Metrics
Book Value / Share (Quarterly)$0.18
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-82.75%
Cash Flow / Share (Quarterly)$-1.41
Price vs S&P 500 (YTD)1.63%
Net Profit Margin (TTM)-65759.09%
EPS (TTM)$-3.19
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-3.19
Revenue Growth (5Y)-47.77%
EPS (Annual)$-2.73
ROI (Annual)-1099.27%
Net Profit Margin (5Y Avg)-57781.84%
Cash / Share (Quarterly)$0.53
ROA (Last FY)-119.94%
EBITD / Share (TTM)$-2.66
ROE (5Y Avg)-289.37%
Operating Margin (TTM)-84709.09%
Cash Flow / Share (Annual)$-1.41
P/B Ratio6.13x
P/B Ratio (Quarterly)4.89x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)810.86x
Net Interest Coverage (TTM)-30.43x
ROA (TTM)-96.29%
EPS Incl Extra (Annual)$-2.73
Current Ratio (Annual)1.67x
Quick Ratio (Quarterly)1.31x
3-Month Avg Trading Volume1.17M
52-Week Price Return-71.35%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)1557.22x
Asset Turnover (Annual)0.00x
52-Week High$5.10
Operating Margin (5Y Avg)-64708.33%
EPS Excl Extra (Annual)$-2.73
CapEx CAGR (5Y)-29.94%
26-Week Price Return-34.91%
Quick Ratio (Annual)1.31x
13-Week Price Return0.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.67x
Enterprise Value$17.839
Revenue / Share Growth (5Y)-62.20%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-279263.64%
Cash / Share (Annual)$0.53
3-Month Return Std Dev73.75%
Net Income / Employee (TTM)$-2
ROE (Last FY)-1099.27%
EPS Basic Excl Extra (Annual)$-2.73
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.19
Receivables Turnover (Annual)0.09x
ROI (TTM)-322.42%
P/S Ratio (TTM)1557.22x
Pretax Margin (5Y Avg)-57838.39%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-106.45%
Year-to-Date Return5.77%
5-Day Price Return22.03%
EPS Normalized (Annual)$-2.73
ROA (5Y Avg)-64.55%
Net Profit Margin (Annual)-279263.64%
Month-to-Date Return35.47%
EBITD / Share (Annual)$-2.65
Operating Margin (Annual)-312631.82%
ROI (5Y Avg)-289.29%
EPS Basic Excl Extra (TTM)$-3.19
P/B Ratio (Annual)4.89x
Pretax Margin (TTM)-65759.09%
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-2.87%
Beta2.30x
Revenue / Share (TTM)$0.00
ROE (TTM)-322.42%
52-Week Low$0.77
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SNTISenti Biosciences, Inc. Common Stock | 1557.22x | — | — | — | $1.14 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Senti Biosciences is a clinical-stage biotech company developing CAR-NK cell therapies—engineered cancer treatments controlled by its proprietary gene circuit platform. Its approach targets cancer cells while preserving healthy tissue, aiming to reduce treatment side effects. Lead candidates include SENTI-202 for various cancers and SENTI-301A for hepatocellular carcinoma.